Cerity Partners LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 40.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 226,777 shares of the medical research company's stock after purchasing an additional 65,262 shares during the period. Cerity Partners LLC owned approximately 0.06% of Thermo Fisher Scientific worth $112,845,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Norges Bank purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $3,149,754,000. GAMMA Investing LLC lifted its position in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after acquiring an additional 1,433,444 shares during the period. Kovitz Investment Group Partners LLC lifted its position in Thermo Fisher Scientific by 1,905.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock valued at $469,889,000 after acquiring an additional 858,193 shares during the period. Finally, Grantham Mayo Van Otterloo & Co. LLC lifted its position in Thermo Fisher Scientific by 140.7% during the 4th quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company's stock valued at $569,062,000 after acquiring an additional 639,467 shares during the period. Institutional investors own 89.23% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently issued reports on TMO shares. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Barclays decreased their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a report on Tuesday, June 24th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, UBS Group cut shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $500.00 to $460.00 in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average target price of $600.30.
Read Our Latest Analysis on Thermo Fisher Scientific
Insider Buying and Selling at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.33% of the stock is currently owned by insiders.
Thermo Fisher Scientific Stock Performance
NYSE TMO traded up $4.29 during trading hours on Friday, hitting $435.02. 2,511,384 shares of the company's stock traded hands, compared to its average volume of 1,995,412. The business's fifty day moving average price is $409.39 and its two-hundred day moving average price is $476.59. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $164.22 billion, a P/E ratio of 25.51, a P/E/G ratio of 2.29 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The firm's quarterly revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the business posted $5.11 earnings per share. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific's payout ratio is currently 10.09%.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
